Spyre Therapeutics, Inc.SYRENASDAQ
Loading
SG&A Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+18.9%
5Y CAGR+18.8%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
+18.9%/yr
vs +22.6%/yr prior
5Y CAGR
+18.8%/yr
Consistent
Acceleration
-3.7pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.4x
Strong expansion
Streak
9 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| TTM | $47.91M | +4.7% |
| 2024 | $45.78M | +14.6% |
| 2023 | $39.95M | +40.0% |
| 2022 | $28.53M | +4.4% |
| 2021 | $27.32M | +35.1% |
| 2020 | $20.22M | +36.3% |
| 2019 | $14.83M | +17.4% |
| 2018 | $12.63M | +25.5% |
| 2017 | $10.07M | +20.0% |
| 2016 | $8.39M | - |